ZIOPHARM Oncology Earnings: Here’s Why Shares are Down Now

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 0.29%.

ZIOPHARM Oncology, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.22 in the quarter versus EPS of $-0.30 in the year-earlier quarter.

Revenue: Was the same at $200,000 as the year-earlier quarter.

Actual vs. Wall St. Expectations: ZIOPHARM Oncology, Inc. reported adjusted EPS loss of $0.22 per share. By that measure, the company beat the mean analyst estimate of $-0.24.

Quoting Management: “We continue to make great strides with our synthetic biology platform, and expect that the coming quarters will be an important period of validation for both our most advanced program, IL-12 DNA, and our various, cutting-edge multi-genic and immunotherapeutic programs, which are rapidly progressing toward the clinic,” said Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. “These technologies, the first to combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale in the life sciences, are revealing the potential for significant therapeutic advances in cancer treatment.”

Key Stats (on next page)…